Over at the Center for Global Development there is much wringing of hands at the worrying news from SE Asia that resistance is beginning to develop to artemisinin-based combination therapies (the most effective treatment for malaria).
The CGD has many worthy suggestions for tackling the problem, including "step-wise containment strategies" and enhancing "drug resistance surveillance efforts."
But everyone - including the NYT journalist who raised the issue last week -- is ignoring the elephant in the dining room: SE Asia has long been awash with fake and substandard artesunate.
Surely this has got more than a little to do with it?
Comments